Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Gu C, Huang H, Han Y. Cost-effectiveness analysis of pharmacokinetic-guided prophylaxis versus standard prophylaxis in adults with severe hemophilia A in China. Adv Ther. 2022;39(8):3777–88.
2. Chen B, Xia A, Yu K. Determination of pharmacokinetic parameters in adult patients with severe hemophilia A and the efficacy of individualized preventive treatment. J Math Med. 2019;32:1590–2.
3. Wu R, Wang X, Zhao X, et al. Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A. Haemophilia. 2022;28:e199-208.
4. Huang K, Wang Y, Zhen Y, et al. Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A. Thromb Res. 2022;213:71–7.
5. Li P, Chen Z, Cheng X, et al. PK- tailored tertiary prophylaxis in patients with severe hemophilia A at Beijing Children’s Hospital. Pediatr Investig. 2019;3:45–9.